# US 2015/0309050 A1 · Diagnostic and therapeutic methods and products related to anxiety disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0309050 A1
- Document ID: US20150309050A1
- Status: Published application
- Kind: A1
- Application number: 13/983,114
- Filed: 2012-02-01
- Published: 2015-10-29
- Earliest claimed: 2012-02-01
- Assignees: University of Vermont and State Agricultural College
- Inventors: Victor May
- Web page: https://patentgrep.com/patent/US20150309050A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/5757: Vasoactive intestinal peptide [VIP] or related peptides
- G01N 2800/301: Anxiety or phobic disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to diagnostic, prognostic and therapeutic methods related to anxiety, as well as related products. In particular examples the anxiety is post-traumatic stress disorder.

## Claims

### Claim 1

A method for diagnosing an anxiety disorder in a female subject, comprising:
a. collecting a tissue sample from the subject;
b. analyzing pituitary adenylate cyclase-activating polypeptide (PACAP) protein expression levels in the tissue sample; and
c. diagnosing the anxiety disorder in the subject having elevated tissue PACAP expression levels as compared to a control tissue sample obtained from a subject who does not have an anxiety disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anxiety disorder is post traumatic stress disorder (PTSD).

### Claim 3 (depends on 2)

The method of claim 2, wherein the female subject exhibits at least one endophenotype of PTSD.

### Claim 4 (depends on 3)

The method of claim 3, wherein the at least one PTSD endophenotype is selected from the group consisting of: intrusive re-experiencing, avoidance, hyperarousal, and fear discrimination.

### Claim 5 (depends on 1)

The method of claim 1, wherein the PACAP expression levels comprises PACAP-38 peptide and PACAP-27 peptide expression levels.

### Claim 6 (depends on 5)

The method of claim 5, wherein the PACAP expression levels comprise PACAP-38 peptide expression levels.

### Claim 7 (depends on 1)

The method of claim 1, wherein the analyzing of PACAP protein expression levels in the tissue sample is by radioimmunoassay.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tissue sample is selected from the group consisting of blood, serum, plasma, and cerebrospinal fluid (CSF).

### Claim 9 (depends on 8)

The method of claim 8, wherein the tissue sample is blood.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject has been exposed to a trauma.

### Claim 11

A method for identifying a subject at risk of developing an anxiety disorder, comprising:
a. collecting a DNA sample from the subject;
b. analyzing the DNA sample for the presence of a SNP in a PAC1 receptor gene; and
c. diagnosing the anxiety disorder in the subject having the SNP in the PAC1 receptor gene.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anxiety disorder is PTSD.

### Claim 13 (depends on 11)

The method of claim 11, wherein the gene encoding the PAC1 receptor is ADCYAP1R1.

### Claim 14 (depends on 11)

The method of claim 11, wherein the SNP is located at position rs2267735 of the ADCYAP1R1 gene.

### Claim 15 (depends on 14)

The method of claim 14, wherein the SNP is a GC allelic mutation.

### Claim 16 (depends on 11)

The method of claim 11, wherein the subject has been exposed to a trauma.

### Claim 17

A method for identifying a subject at risk of developing an anxiety disorder, comprising:
a. collecting a DNA sample from the subject;
b. analyzing the DNA sample for epigenetic methylation at a first site within a ADCYAP1R1 CpG island; and
c. diagnosing the anxiety disorder in the subject having elevated levels of epigenetic methylation.

### Claim 18 (depends on 17)

The method of claim 17, wherein the anxiety disorder is PTSD.

### Claim 19

A method of treating an anxiety disorder in a female subject in need thereof, comprising administering to the subject a therapeutically effective amount of a PACAP inhibitor.

### Claim 20 (depends on 19)

The method of claim 19, wherein the anxiety disorder is PTSD.

### Claim 21 (depends on 19)

The method of claim 19, wherein the PACAP inhibitor is truncated PACAP peptide.

### Claim 22 (depends on 19)

The method of claim 19, wherein the truncated PACAP peptide is PACAP-38 or PACAP-27.

### Claim 23 (depends on 19)

The method of claim 19, wherein the PACAP inhibitor is in a form selected from the group consisting of: a small molecule drug, small interfering RNA (siRNA), and an antibody.

### Claim 24 (depends on 23)

The method of claim 23, wherein the PACAP inhibitor is selected from the group consisting of: a deletion variant of maxadilan, an acyl hydride, a JNK/p38 inhibitor, a histone deactylase inhibitor, sodium butyrate, trichostatin A, and a BMP molecule.

### Claim 25 (depends on 24)

The method of claim 24, wherein the deletion variant of maxadilan is MaxD4 or M65.

### Claim 26

A DNA amplification kit for diagnosing an anxiety disorder in a female subject, comprising:
a. two or more oligonucleotide primers capable of binding to DNA sequence flanking position rs2267735 of the ADCYAP1R1 gene;
b. optimization buffer;
c. polymerase; and
d. deoxyribonucleotide triphophates (dNTPs);
wherein each of elements a-d is arranged in one or more containers.

### Claim 27

An immunoassay kit for diagnosing an anxiety disorder in a female subject, comprising:
a. a primary IgG anti-PACAP antibody;
b. an anti-IgG immuno-conjugated secondary antibody;
c. diluent and wash buffers;
d. chromagen; and
e. pre-coated microplate;
wherein each of elements a-e is arranged in one or more containers.

### Claim 28

A gene chip comprising a solid surface, having attached thereto a plurality of oligonucleotides, wherein the oligonucleotides have a sequence complementary to a portion of a PAC1 receptor gene or a flanking sequence thereof, wherein at least some of the portions of the PAC1 receptor gene have a SNP.

### Claim 29 (depends on 28)

A gene chip kit for diagnosing an anxiety disorder in a female subject, comprising:
a. a micro gene chip of claim 28;
b. a hybridization buffer;
c. a stain solution; and
d. a wash buffer;
wherein each of elements a-d is arranged in one or more containers.

### Claim 30

A composition comprising an 8-9 amino acid peptide of SEQ ID NO:3 or SEQ ID NO:4.

### Claim 31

An antibody that binds specifically to an epitope at the carboxy-terminal end of PACAP.

### Claim 32 (depends on 30)

The antibody of claim 30, wherein the epitope is SEQ ID NO:3 or SEQ ID NO:4.

### Claim 33

A composition comprising an antibody that binds specifically to a peptide of SEQ ID NO:3 or SEQ ID NO:4.
